Biohaven Pharmaceutical (NYSE:BHVN)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research note issued to investors on Monday, The Fly reports. They presently have a $134.00 price target on the stock, up from their previous price target of $92.00. Mizuho’s price target would suggest a potential upside of 14.01% from the stock’s current price.
A number of other research firms have also recently weighed in on BHVN. Cowen boosted their price objective on shares of Biohaven Pharmaceutical from $90.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, July 7th. HC Wainwright boosted their price objective on shares of Biohaven Pharmaceutical from $111.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday. SVB Leerink lowered their target price on shares of Biohaven Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Wednesday, May 12th. Cantor Fitzgerald boosted their target price on shares of Biohaven Pharmaceutical from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday, June 1st. Finally, Morgan Stanley lowered their target price on shares of Biohaven Pharmaceutical from $76.00 to $69.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $111.00.
BHVN stock opened at $117.53 on Monday. Biohaven Pharmaceutical has a twelve month low of $57.66 and a twelve month high of $119.27. The company has a market capitalization of $7.65 billion, a PE ratio of -8.29 and a beta of 1.01. The company’s fifty day moving average price is $88.29.
Man who called the 2020 crash 45 days early shares “alarming” signals from the stock market today and what it means for July…
Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Sunday, May 9th. The company reported ($4.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.92) by ($1.29). The business had revenue of $43.82 million for the quarter, compared to analyst estimates of $36.46 million. During the same quarter last year, the business earned ($2.39) EPS. The firm’s revenue was up 3710.4% on a year-over-year basis. As a group, sell-side analysts expect that Biohaven Pharmaceutical will post -12.62 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in BHVN. Valeo Financial Advisors LLC lifted its stake in Biohaven Pharmaceutical by 195.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 295 shares of the company’s stock worth $25,000 after acquiring an additional 195 shares during the period. Canada Pension Plan Investment Board lifted its stake in Biohaven Pharmaceutical by 120.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 363 shares of the company’s stock worth $31,000 after acquiring an additional 198 shares during the period. Lazard Asset Management LLC purchased a new stake in Biohaven Pharmaceutical in the fourth quarter worth about $53,000. WASHINGTON TRUST Co lifted its stake in Biohaven Pharmaceutical by 137.5% in the first quarter. WASHINGTON TRUST Co now owns 950 shares of the company’s stock worth $65,000 after acquiring an additional 550 shares during the period. Finally, Elkhorn Partners Limited Partnership purchased a new stake in Biohaven Pharmaceutical in the first quarter worth about $68,000. 91.46% of the stock is owned by institutional investors.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
Recommended Story: What is Blockchain?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What are gap-down stocks?
7 Low-Priced Dividend Stocks Under $10
The recent trading activity surrounding low-priced stocks like GameStop (NYSE:GME) is a reminder to investors of the high-risk nature involved with these stocks. Often when a stock trades for under $10 (also termed a penny stock), it is trading that low for a reason. The company may not be profitable, or in the case of GameStop, it finds itself with a business model that no longer fits with consumer trends.
But that’s not always the case. It is possible to find low-priced stocks, even penny stocks, that offer great value. This is particularly true if the stock offers investors a dividend. Dividend-earning stocks are a diversification source for a consumer’s portfolio, particularly if the dividend gets reinvested. It’s literally like paying yourself for owning the stock.
And the stocks in this presentation look ready also to deliver some additional stock price growth that can increase your total return.
